logo
logo

Onl Therapeutics Closes 2Nd Tranche Of $46.9 Million Series B Financing Upon Achieving Onl1204 Development Milestones

Onl Therapeutics Closes 2Nd Tranche Of $46.9 Million Series B Financing Upon Achieving Onl1204 Development Milestones

01/13/22, 7:00 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgann arbor
Money raised
$46.9 million
Round Type
series b
ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced it has closed on its second tranche of the Company’s Series B financing. The total proceeds raised in the Series B was $46.9 million.

Company Info

Company
Onl Therapeutics
Location
ann arbor, michigan, united states
Additional Info
The company is also conducting a Phase 1b clinical trial in patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD) and a Phase 1b clinical trial in patients with progressing open-angle glaucoma.